With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.163765-44-4,(R)-1-Boc-3-Methylpiperazine,as a common compound, the synthetic route is as follows.
(R)-Terf-butyl 3-methylpiperazine-1 -carboxylate (1 .77 g, 8.82 mmol) and glacial acetic acid (530 mg, 505 muIota_, 8.82 mmol) were added to a stirred solution of 7-bromo-5-methyl-4-oxo-4,5- dihydrothieno[3,2-c]pyridine-2-carbaldehyde (for a preparation see Intermediate 3, 2.0 g, 7.35 mmol) in dichloromethane (50 ml_). The reaction mixture was stirred at room temperature for 30 minutes then treated with sodium triacetoxyborohydride (7.79 g, 36.7 mmol). The reaction mixture was stirred at room temperature for 8 hours then allowed to stand overnight. Saturated sodium bicarbonate solution (75 ml.) was added and the mixture stirred for 10 minutes. The organic phase was separated and the aqueous phase extracted with dichloromethane (2 x 50 ml_). The combined organics were dried and evaporated. The residue was purified by chromatography on silica gel eluting with 3% methanol in dichloromethane, followed by trituration with diethyl ether gave (R)-tert- butyl 4-((7-bromo-5-methyl-4-oxo-4,5-dihydrothieno[3,2-c]pyridin-2-yl)methyl)-3-methylpiperazine-1 – carboxylate (3.1 g, 6.79 mmol, 92% yield) as a yellow solid. LCMS (2 min, Formic Acid): Rt = 0.77 min, MH+ = 456/458.
163765-44-4, The synthetic route of 163765-44-4 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; GLAXOSMITHKLINE LLC; AMANS, Dominique; BAMBOROUGH, Paul; BIT, Rino, Antonio; BROWN, John, Alexander; CAMPBELL, Matthew; LINDON, Matthew, John; SHIPLEY, Tracy, Jane; THEODOULOU, Natalie, Hope; WELLAWAY, Christopher, Roland; WESTAWAY, Susan, Marie; WO2014/78257; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics